A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : R-ISS / Revised International Staging System

[Related PubMed/MEDLINE]
Total Number of Papers: 74
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   R-ISS  (>> Co-occurring Abbreviation)
Long Form:   Revised International Staging System
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2023 A prognostic model incorporating inflammatory cells and cytokines for newly diagnosed multiple myeloma patients. IL-10, IL-1beta, IL-2R, IL-6, IL-8, ISS, LASSO, LMR, MM, NLR, PLR, SIRI, TNF-alpha
2023 Experts' consensus on the definition and management of high risk multiple myeloma. EMN, HR, HRMM, MM
2023 The prognostic utility of dynamic risk stratification at disease progression in patients with multiple myeloma. ISS, MM, mPPS
2022 A stratified therapeutic model incorporated with studies on regulatory B cells for elderly patients with newly diagnosed multiple myeloma. Bd, CEMM2021, MM, NDMM, OS, PFS, PR
2022 Amp 1q21 is more predictable with dismal survival than gain 1q21 of newly diagnosed multiple myeloma in real-world analysis. amp, FISH, HRCA, MM, NDMM, ORR, OS, PFS
2022 Characteristics and clinical outcome of high-risk multiple myeloma patients in Korea (KMM 1805). KMR, MM, OS, PFS
2022 Diagnosis and treatment of multiple myeloma in Hunan Province. DS, HQR, ISS, MM, NDMM, ORR
2022 Different expression patterns of VISTA concurrent with PD-1, Tim-3, and TIGIT on T cell subsets in peripheral blood and bone marrow from patients with multiple myeloma. beta2-MG, BM, ECOG, HIs, MM, PB, PD-1, TIGIT, Tim-3, Treg, VISTA
2022 Exploring the R-ISS stage-specific regular networks in the progression of multiple myeloma at single-cell resolution. MM
10  2022 Heterogeneity in long term outcomes for R-ISS stage II in newly diagnosed multiple myeloma patients. CA
11  2022 Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis by Prior Transplantation. CI, HR, Isa, MM, PFS, RRMM, TEAEs
12  2022 Myocardial Injury in Multiple Myeloma Patients With Preserved Left Ventricular Ejection Fraction: Noninvasive Left Ventricular Pressure-Strain Myocardial Work. AUC, CAEs, GLS, GWE, GWI, LVEF, LVMW, LVMWE, LVMWI, MM
13  2022 Relation of whole-body metabolic tumor volume and total lesion glycolysis on fluorodeoxyglucose PET/computed tomography with clinical and laboratory parameters in newly diagnosed multiple myeloma. BM, MM, TLG, WBMTV
14  2022 Revised International Staging System (R-ISS) stage-dependent analysis uncovers oncogenes and potential immunotherapeutic targets in multiple myeloma (MM). EBV, MM, PC, RRM2
15  2022 Risk Stratification Before and During Treatment in Newly Diagnosed Multiple Myeloma: From Clinical Trials to the Real-World Setting. MM, MRD, ND
16  2022 Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. EMN, NDMM, OS, PFS
17  2022 The applicability of the Second Revision of the International Staging System for patients with multiple myeloma receiving immunomodulatory drugs or proteasome inhibitor-based regimens as induction treatment: A real-world analysis. OS, PFS
18  2022 The level and integrity of plasma circulating cell-free DNA in patients with primary multiple myeloma. cfDNA, DS, ISS, MM, PFS, qPCR, VGPR
19  2022 Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group. ISS, MM
20  2021 A prognostic survival model based on metabolism-related gene expression in plasma cell myeloma. PCM
21  2021 Correlations between apparent diffusion coefficient values of WB-DWI and clinical parameters in multiple myeloma. ADC, beta2-MG, MM, WB-DWI
22  2021 Current Approach to Managing Patients with Newly Diagnosed High-Risk Multiple Myeloma. DRD, mAb, MRD, PI
23  2021 Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and 18F-FDG PET/CT. 18F-FDG, FL, MM, NDMM, PET/CT
24  2021 Evaluation of prognostic staging systems of multiple myeloma in the era of novel agents. Hgb, MM, OS
25  2021 Favorable Long-Term Outcomes with Autologous Stem Cell Transplantation for High-Risk Multiple Myeloma Patients with a Positive Result On 18F-FDG PET/CT at Baseline. ASCT, EMD, FL, HDT, NDMM, OS, PFS
26  2021 Histogram Analysis Based on Apparent Diffusion Coefficient Maps of Bone Marrow in Multiple Myeloma: An Independent Predictor for High-risk Patients Classified by the Revised International Staging System. ADC, DI, NDMM, OR, ROC, SD
27  2021 Multiple Extramedullary-Bone Related and/or Extramedullary Extraosseous Are Independent Poor Prognostic Factors in Patients With Newly Diagnosed Multiple Myeloma. EM, EMB, EME, EMM, MM, OS, PFS
28  2021 Prognostic value of circulating clonal plasma cells in newly diagnosed multiple myeloma. CPC, MM
29  2021 Propensity-score matched analysis of the efficacy of maintenance/continuous therapy in newly diagnosed patients with multiple myeloma: a multicenter retrospective collaborative study of the Japanese Society of Myeloma. MM, OS, PFS
30  2021 Role of whole-body diffusion-weighted imaging in evaluation of multiple myeloma. ADC, MM, WB-DWI
31  2021 The association of mobilising regimen on immune reconstitution and survival in myeloma patients treated with bortezomib, cyclophosphamide and dexamethasone induction followed by a melphalan autograft. CY, OS, TTNT
32  2021 The detection of circulating plasma cells may improve the Revised International Staging System (R-ISS) risk stratification of patients with newly diagnosed multiple myeloma. CPCs, LDH, MM, OS, PFS
33  2021 [Analysis of the clinical effects and outcome of patients with double-hit high-risk multiple myeloma]. MM, OS, PFS, RVD
34  2021 [Predictive Value of Newly Diagnosed IgG Level in Patients with IgG-type Multiple Myeloma after Initial Treatment]. ASCT, BMPC, LDH, MM
35  2020 18F-FDG and 11C-Methionine PET/CT in Newly Diagnosed Multiple Myeloma Patients: Comparison of Volume-Based PET Biomarkers. 11C-MET, 18F-FDG, B2M, FL, FLC, LDH, MM, PET, SUV, TLG, TMTV
36  2020 A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. MM, ND, OS, PFS, PI
37  2020 A Tangle of Genomic Aberrations Drives Multiple Myeloma and Correlates with Clinical Aggressiveness of the Disease: A Comprehensive Review from a Biological Perspective to Clinical Trial Results. MM
38  2020 Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents. C1As, HRCAs, MM, OS
39  2020 Circulating miR-451a levels as a potential biomarker to predict the prognosis of patients with multiple myeloma. BM, IL-6R, MFC, MM, MRD
40  2020 Cytogenetics and Revised International Staging System (R-ISS): Risk Stratification in Multiple myeloma - A Retrospective Study in Indian Population. FISH, iFISH, MM
41  2020 Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients. HR, MM, OS, PFS
42  2020 Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. FISH, MM, OS, PCPro, PFS
43  2020 miR-451a suppression of IL-6R can inhibit proliferation and increase apoptosis through the JAK2/STAT3 pathway in multiple myeloma. BM, IL-6, MM
44  2020 Multiple Myeloma in Hispanics: Incidence, Characteristics, Survival, Results of Discovery, and Validation Using Real-World and Connect MM Registry Data. MM, NHB, NHW
45  2020 NUPR1 Silencing Induces Autophagy-Mediated Apoptosis in Multiple Myeloma Cells Through the PI3K/AKT/mTOR Pathway. DS, MM, NUPR1
46  2020 Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma: the HOVON-87/NMSG-18 trial. HR, MM, MPT-T, OS, SR
47  2020 Serum-free light chains combined with the Revised International Staging System could further distinguish the superior and inferior clinical outcome of multiple myeloma patients. MM, MR-ISS, NDMM, sFLC
48  2019 Clinical characteristics and prognosis of immunoglobulin D myeloma in the novel agent era. FISH, IgD
49  2019 Evaluation of the Revised International Staging System (R-ISS) in Japanese patients with multiple myeloma. OS
50  2019 High Expression Levels of Long Noncoding RNA Small Nucleolar RNA Host Gene 18 and Semaphorin 5A Indicate Poor Prognosis in Multiple Myeloma. DS, ISS, MM, OS, SNHG18
51  2019 Improved survival outcomes and relative youthfulness of multiple myeloma patients with t(4;14) receiving novel agents are associated with poorer performance of the revised international staging system in a real aging society. MM, OS
52  2019 Next Generation Sequencing-based Validation of the Revised International Staging System for Multiple Myeloma: An Analysis of the MMRF CoMMpass Study. CAs, FISH, MMRF, NGS, R-ISS-NGS
53  2019 Role of Conventional Karyotyping in Multiple Myeloma in the Era of Modern Treatment and FISH Analysis. HR, OS
54  2019 [A Patient Surviving More Than Five Years Due to the Effect of Sequential Alternating Chemotherapy Administered to Metachronous Overlapping Cancer of Multiple Myeloma and StageⅣ EGFR Positive Non-Small Cell Lung Cancer]. aPBSCT, CR, GEF, PD
55  2018 18F-FDG PET/CT is useful for determining survival outcomes of patients with multiple myeloma classified as stage II and III with the Revised International Staging System. EMD, FLs, MM, OS, PFS
56  2018 Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients. ASCT, CA, MM, OS
57  2018 Nucleic acid based risk assessment and staging for clinical practice in multiple myeloma. CA, FISH, LDH, MLPA, MM, OS, PFS, qRT-PCR
58  2018 Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma. AHCT, MM, OS, PFS
59  2018 Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups. AHCT, CI, IMWG 2014, MM, OS
60  2018 Successful Use of Intravenous Immunoglobulin G to Treat Refractory Heparin-Induced Thrombocytopenia With Thrombosis Complicating Peripheral Blood Stem Cell Harvest. ---
61  2018 The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma. FLs, GEP, MM, OS, PFS
62  2018 The Role of 18F-FDG PET/CT in Multiple Myeloma Staging according to IMPeTUs: Comparison of the Durie-Salmon Plus and Other Staging Systems. DS Plus, DSS, IMPeTUs, MM, OS
63  2018 Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies. IMWG, MM, OS
64  2017 Automatic digital quantification of bone marrow myeloma volume in appendicular skeletons - clinical implications and prognostic significance. MDCT, MM
65  2017 Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma. NDMM, OS, PFS, RRMM
66  2017 Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy. CI, MM, OS
67  2017 High serum lactate dehydrogenase predicts an unfavorable outcome in Chinese elderly patients with multiple myeloma. LDH, MM, ORR, OS, PFS
68  2017 The Revised International Staging System Compared to the Classical International Staging System Better Discriminates Risk Groups among Transplant-Ineligible Multiple Myeloma Patients. ISS, MM, OS
69  2017 [Outcomes of lenalidomide-based treatment for 57 patients of relapsed or refractory multiple myeloma]. AEs, CR, DOR, ISS, MM, MR, ORR, OS, PFS, PR, VGPR
70  2017 [Prognostic value of the revised international staging system for newly diagnosed multiple myeloma patients]. MM
71  2016 Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma. ---
72  2016 Revised International Staging System Applied to Real World Multiple Myeloma Patients. ISS
73  2016 Risk Stratification in Multiple Myeloma. ISS
74  2016 [Analysis of serum free light chains kappa/lamda ratio and heavy/light chain pairs of immunoglobulin to the stratification of multiple myeloma according to Mayo Stratification of Myeloma and Revised International Staging System]. DS, ISS, MM, mSMART